Amphastar Pharmaceuticals, Inc. — Director's Dealing 2018

Mar 21, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Amphastar Pharmaceuticals, Inc. (AMPH)
CIK: 0001297184
Period of Report: 2018-03-16

Reporting Person: Shandell Jason B. (Director, President and General Counsel)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-03-16	Common Stock	F	5495	$19.91	Disposed	251372	Direct
2018-03-17	Common Stock	F	6486	$19.91	Disposed	244886	Direct
2018-03-19	Common Stock	S	11707	$19.3702	Disposed	233179	Direct
2018-03-20	Common Stock	S	8293	$19.519	Disposed	224886	Direct

Footnotes

F1: The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units, or RSUs.

F2: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 14, 2017.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.05 to $19.62 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.39 to $19.91, inclusive.